Oligonucleotides as therapeutic agents
著者
書誌事項
Oligonucleotides as therapeutic agents
（Ciba Foundation symposium, 209）
Wiley, 1997
大学図書館所蔵 件 / 全9件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Proceedings of the Symposium on Oligonucleotides as Therapeutic Agents, held at Ciba Foundation on 7-9 January 1997
Includes index
Symposium on Oligonucleotides as therapeutic agents, held at the Ciba Foundation on 7-9 January 1997
Includes bibliographical references and index
内容説明・目次
内容説明
A work that includes discussion of the chemistry of oligonucleotide analogues, and reports on structure activity studies and current clinical trials, concluding with reviews of applications of ribozymes (RNA enzymes that catalyse RNA cleavage), of aptamers (oligonucleotides which bind specifically to proteins), and discussion of triplex-forming oligonucleotides. The book draws on contributions from an interdisciplinary and international group of specialists concerned with research on all aspects of the use of oligonucleotides as therapeutic agents. Coverage ranges from discussion of the basic chemistry of oligonucleotide synthesis through to the problems of drug delivery and mechanisms of action. It features data from ongoing clinical trials of these highly experimental agents.
目次
- Oligonucleotide analogues - an overview
- phosphorothioate oligodeoxynucleotides - large scale synthesis and analysis, impurity characterization and the effects of phosphorous stereochemistry
- discovering antisense reagents by hybridization of RNA to oligonucleotide arrays
- pharmacokinetics of oligonucleotides in cell culture
- pharmacokinetics of antisense oligonucleotides
- cellular pharmacology of antisense oligodeoxynucleotides
- sequence-specific control of gene expression by antigene and clamp oligonucleotides
- differential oligonucleotide activity in cell culture versus mouse models
- structure-activity relationships in cell culture
- progress in antisense therapeutics
- treating human myelogenous leukaemia with oligonucleotides targeted to the C-Myb gene - two years clinical experience
- therapeutic applications of catalytic antisense RNA's
- exogenous application of ribozymes for the inhibition of gene expression
- SELEX derived drugs
- in vivo production of oligonucleotide applications for antisense DNA.
「Nielsen BookData」 より